Literature DB >> 1705714

Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression.

W E Mercer1, M T Shields, D Lin, E Appella, S J Ullrich.   

Abstract

The p53 gene is a frequent target of mutation in a wide variety of human cancers. Previously, it was reported that conditional expression of wild-type p53 protein in a cell line (GM47.23) derived from a human glioblastoma multiform tumor had a negative effect on cell proliferation. We have now investigated the effect that induction of wild-type p53 protein in this cell line has on the expression of the proliferating-cell nuclear antigen gene. The proliferating-cell nuclear antigen gene encodes a nuclear protein that is an auxiliary factor of DNA polymerase delta and part of the DNA replication machinery of the cell. We show that inhibition of cell cycle progression into S-phase after induction of wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen mRNA and protein expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705714      PMCID: PMC51145          DOI: 10.1073/pnas.88.5.1958

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

Review 1.  p53: oncogene or anti-oncogene?

Authors:  D P Lane; S Benchimol
Journal:  Genes Dev       Date:  1990-01       Impact factor: 11.361

Review 2.  The p53 cellular tumor antigen: gene structure, expression and protein properties.

Authors:  M Oren
Journal:  Biochim Biophys Acta       Date:  1985-11-12

3.  Monoclonal antibodies specific for simian virus 40 tumor antigens.

Authors:  E Harlow; L V Crawford; D C Pim; N M Williamson
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

4.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

5.  Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.

Authors:  J R Bischoff; P N Friedman; D R Marshak; C Prives; D Beach
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  Suppression of human colorectal carcinoma cell growth by wild-type p53.

Authors:  S J Baker; S Markowitz; E R Fearon; J K Willson; B Vogelstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

7.  Mechanisms of p53 loss in human sarcomas.

Authors:  L M Mulligan; G J Matlashewski; H J Scrable; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

8.  Transforming potential of deletion mutants of the SV40 T antigen coding gene in Syrian hamster cells.

Authors:  R R Hirschhorn; W E Mercer; H T Liu; R Baserga
Journal:  Virology       Date:  1984-04-15       Impact factor: 3.616

9.  Monoclonal antibodies against simian virus 40 T antigens: evidence for distinct sublcasses of large T antigen and for similarities among nonviral T antigens.

Authors:  E G Gurney; R O Harrison; J Fenno
Journal:  J Virol       Date:  1980-06       Impact factor: 5.103

10.  Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed.

Authors:  P Gunning; P Ponte; H Okayama; J Engel; H Blau; L Kedes
Journal:  Mol Cell Biol       Date:  1983-05       Impact factor: 4.272

View more
  60 in total

Review 1.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

2.  Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.

Authors:  J Jankowski; G Coghill; D Hopwood; K G Wormsley
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

3.  Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase.

Authors:  D Lin; M T Shields; S J Ullrich; E Appella; W E Mercer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

4.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

5.  Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein.

Authors:  G Farmer; P Friedlander; J Colgan; J L Manley; C Prives
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

6.  Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene.

Authors:  J Zhao; F I Schmieg; D T Simmons; G R Molloy
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index.

Authors:  V Gorgoulis; V Zoumpourlis; G Rassidakis; A Karameris; C Barbatis; D A Spandidos; C Kittas
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder.

Authors:  F Atuğ; L Türkeri; M Ozyürek; A Akdaş
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

9.  Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas--an enhanced immunohistochemical approach.

Authors:  M Saegusa; Y Takano; H Kishimoto; G Wakabayashi; K Nohga; M Okudaira
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

10.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.